Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SNRNP200 | O75643 | 5/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31284744 | 0.91 | SNRNP200 (0.42) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30599100 | 0.87 | SNRNP200 (0.41) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31284947 | 0.85 | SNRNP200 (0.41) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30599098 | 0.85 | SNRNP200 (0.41) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30599101 | 0.85 | SNRNP200 (0.41) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30886401 | 0.83 | SNRNP200 (0.38) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30886450 | 0.81 | PDE10A (0.38) | PDE10A | |
| SCHEMBL25432813 | 0.81 | L3MBTL1 (0.44) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25436435 | 0.81 | L3MBTL1 (0.44) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26923787 | 0.81 | L3MBTL1 (0.44) | L3MBTL1SNRNP200CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598927-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2025054366-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4486722-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119137101-A | Compounds, compositions, and methods | 尼科治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024077273-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | L3MBTL1 864/4885SNRNP200 3391/4885CHRNB2 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.